349 related articles for article (PubMed ID: 36993952)
1. Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis.
Wu J; Ni T; Deng R; Li Y; Zhong Q; Tang F; Zhang Q; Fang C; Xue Y; Zha Y; Zhang Y
Front Immunol; 2023; 14():1065510. PubMed ID: 36993952
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Pneumonitis with combined immune checkpoint inhibitors and chemoradiotherapy in locally advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang L; Li B; Xu Y; Zou B; Fan B; Wang C; Wang L
Future Oncol; 2023 May; 19(16):1151-1160. PubMed ID: 37293787
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of concurrent immune checkpoint inhibitors combined with radiotherapy or chemoradiotherapy for advanced non-small cell lung cancer: A systematic review and single-arm meta-analysis.
Cui R; Li Y; Yu X; Wei C; Jiang O
PLoS One; 2024; 19(6):e0304941. PubMed ID: 38865375
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis.
Wu J; Deng R; Ni T; Zhong Q; Tang F; Li Y; Zhang Y
Front Oncol; 2022; 12():887525. PubMed ID: 35992797
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.
Yang Y; Wang J; Zhang T; Zhou Z; Wang Y; Jiang Y; Liu W; Xiao Z; Deng L; Feng Q; Wang X; Lv J; Wang W; Xue Q; Wang J; Li YX; Bi N
Front Immunol; 2023; 14():1281888. PubMed ID: 38077319
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
Balasubramanian A; Onggo J; Gunjur A; John T; Parakh S
Clin Lung Cancer; 2021 Mar; 22(2):74-82. PubMed ID: 33414053
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
Yang Y; Deng L; Yang Y; Zhang T; Wu Y; Wang L; Bi N
Clin Lung Cancer; 2022 Mar; 23(2):95-107. PubMed ID: 34284948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Liu Z; Xu T; Chang P; Fu W; Wei J; Xia C; Wang Q; Li M; Pu X; Huang F; Ge C; Gao Y; Gong S; Liu C; Dong L
Front Pharmacol; 2023; 14():1064227. PubMed ID: 36762107
[No Abstract] [Full Text] [Related]
12. [Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qin Q; Wang J; Wang H
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):772-791. PubMed ID: 32752580
[TBL] [Abstract][Full Text] [Related]
13. Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review.
Li B; Jiang C; Pang L; Zou B; Ding M; Sun X; Yu J; Wang L
Front Immunol; 2021; 12():627197. PubMed ID: 33859637
[TBL] [Abstract][Full Text] [Related]
14. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non-small cell lung cancer: Chinese multicenter report and literature review.
Zhang T; Xu K; Bi N; Zhang L; Jiang W; Liang J; Deng L; Wang X; Wang J; Wang J; Wang L
Thorac Cancer; 2020 Oct; 11(10):2916-2923. PubMed ID: 32833338
[TBL] [Abstract][Full Text] [Related]
16. Evaluation safety and efficacy of immune checkpoint blockers (ICB) and radiotherapy combination versus ICB in non-small cell lung cancer patients with recurrence or metastasis: A systematic review and meta-analysis.
Zeng Y; Zhang L; Liang Y; Zhang X; Li L; Wang M; Guo J; Li Q; Cao J; Gu JJ; Wang B
Cancer Med; 2023 Jul; 12(13):13928-13941. PubMed ID: 37323098
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of combination therapy with immune checkpoint inhibitors in non-small cell lung cancer: A meta-analysis.
Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
Int Immunopharmacol; 2021 Jul; 96():107594. PubMed ID: 33798808
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
[TBL] [Abstract][Full Text] [Related]
19. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
20. Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
Wang Y; Zhang T; Wang J; Zhou Z; Liu W; Xiao Z; Deng L; Feng Q; Wang X; Lv J; Ma X; Xue Q; Wang J; Wang Z; Bi N
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):590-600. PubMed ID: 36623605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]